Clinical Research Directory

Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Life expectancy of ≥ 6 months. * Stage IV squamous NSCLC as defined by American Joint Committee on Cancer (AJCC) 9th Edition. * Measurable disease according to RECIST v1.1 as determined by the investigator and documented prior to starting induction therapy. * Programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) \< 50% as assessed per local testing. To minimize assay variability, local laboratory must ascertain PD-L1 status using the PD-L1 Immunohistochemistry (IHC) 22C3 pharmDx assay. Key Exclusion Criteria: * Nonsquamous histology NSCLC. * Tumor invasion, encasement of organs, or major blood vessels, if poses a significant increased risk of bleeding. * Targetable genomic aberrations for which approved targeted therapy is available. * The participant has uncontrolled, significant intercurrent or recent illness. * Active autoimmune disease or a history of autoimmune disease within 2 years prior to the first dose of induction therapy requiring systemic immunosuppressive therapy. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.